Immunology

Question 1

Alemtuzumab

Answer 1

Target:
CD52

Use:
CLL

Question 2

Bevacizumab

Answer 2

Target:
VEGF

Use:

• Colorectal cancer
• RCC

Question 3

Cetuximab

Answer 3

Target: EGFR

Use: Stage IV colorectal cancer, head and neck cancer

Question 4

Rituximab

Answer 4

Target: CD20

Use: B- cell non-Hodgkin lymphoma, rheumatoid arthritis (with MTX), ITP

Question 5

Trastuzumab

Answer 5

Target: HER2/neu

Use: Breast cancer, gastric cancer

HER2- “trans2zumab”

Question 6

Infliximab, adalimumab

Answer 6

Target: TNF- α

Use: IBD, rheumatoid arthritis, ankylosing sponylitis, psoriasis

Rheumatoid arthritis “inflix” pain in “ da limbs”

Question 7

Natalizumab

Answer 7

Target: α4-integrin

Use: Multiple sclerosis, Crohn disease

α4-integrin; leukocytes adhesion. Risk of PML in patients with JC virus

Question 8

Abciximab

Answer 8

Target: Glycoprotein IIb/IIIa

Use: Antiplatelet agent for prevention of ischemic complications in patients undergoing percutaneous cornorary intervention

IIb times IIIa equals “absiximab”

Question 9

Denosumab

Answer 9

Target: RANKL

Use: Osteoporosis, inhibits osteoclast maturation (mimics osteoprotegrin)

Denosumab affects osteoclasts

Question 10

Digoxin immune

Answer 10

Target: Digoxin

Use: Antidote for digoxin toxicity

Question 11

Omalizumab

Answer 11

Target: IgE

Use: Allergic asthma; prevents IgE binindg to FcεRI

Question 12

Palivizumab

Answer 12

Target: RSV F protein

Use: RSV prophylaxis for high-risk infants

PaliVIzumab - VIrus